Incannex Healthcare Limited (IXHL)
USD 0.62
(7.89%)
USD 0.62
(7.89%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 | 30.05 Million USD | -39.49% |
| 2023 | 21.35 Million AUD | 36.15% |
| 2022 | 15.68 Million AUD | 68.41% |
| 2021 | 9.31 Million AUD | 215.17% |
| 2020 | 2.95 Million AUD | -12.68% |
| 2019 | 3.38 Million AUD | -8.68% |
| 2018 | 3.7 Million AUD | -1.89% |
| 2017 | 3.77 Million AUD | 388.72% |
| 2016 | 772.94 Thousand AUD | -69.06% |
| 2015 | 2.49 Million AUD | -62.6% |
| 2014 | 6.68 Million AUD | -39.19% |
| 2013 | 10.98 Million AUD | 223.02% |
| 2012 | 3.4 Million AUD | -27.31% |
| 2011 | 4.67 Million AUD | 144.92% |
| 2010 | 1.91 Million AUD | -52.36% |
| 2009 | 4 Million AUD | 199.27% |
| 2008 | 1.33 Million AUD | 20.13% |
| 2007 | 1.11 Million AUD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q4 | 6.47 Million USD | 22.21% |
| 2024 Q3 | 7.41 Million USD | 41.08% |
| 2024 Q2 | 5.25 Million USD | 90.34% |
| 2024 Q1 | 7.5 Million USD | -4.37% |
| 2023 Q3 | 3.73 Million USD | 25.6% |
| 2023 Q2 | 2.97 Million USD | -92.49% |
| 2023 Q1 | 39.59 Million USD | 470.06% |
| 2023 Q4 | 7.84 Million USD | 110.08% |
| 2023 FY | 21.35 Million AUD | 36.15% |
| 2022 FY | 15.68 Million AUD | 68.41% |
| 2022 Q4 | 6.94 Million USD | 0.0% |
| 2021 FY | 9.31 Million AUD | 215.17% |
| 2020 FY | 2.95 Million AUD | -12.68% |
| 2019 FY | 3.38 Million AUD | -8.68% |
| 2018 FY | 3.7 Million AUD | -1.89% |
| 2017 FY | 3.77 Million AUD | 388.72% |
| 2016 FY | 772.94 Thousand AUD | -69.06% |
| 2016 Q3 | 117.98 Thousand AUD | -14.67% |
| 2016 Q4 | 117.98 Thousand AUD | 0.0% |
| 2016 Q1 | 138.25 Thousand AUD | 0.0% |
| 2016 Q2 | 138.25 Thousand AUD | 0.0% |
| 2015 Q1 | -3.3 Million AUD | 0.0% |
| 2015 FY | 2.49 Million AUD | -62.6% |
| 2015 Q4 | 138.25 Thousand AUD | 0.0% |
| 2015 Q3 | 138.25 Thousand AUD | 104.18% |
| 2015 Q2 | -3.3 Million AUD | 0.0% |
| 2014 Q2 | -10.18 Thousand AUD | 0.0% |
| 2014 FY | 6.68 Million AUD | -39.19% |
| 2014 Q3 | -3.3 Million AUD | -32362.09% |
| 2014 Q4 | -3.3 Million AUD | 0.0% |
| 2014 Q1 | -10.18 Thousand AUD | 0.0% |
| 2013 Q4 | -10.18 Thousand AUD | 0.0% |
| 2013 Q1 | 580.52 Thousand AUD | 0.0% |
| 2013 Q2 | 580.52 Thousand AUD | 0.0% |
| 2013 FY | 10.98 Million AUD | 223.02% |
| 2013 Q3 | -10.18 Thousand AUD | -101.75% |
| 2012 FY | 3.4 Million AUD | -27.31% |
| 2012 Q4 | 580.52 Thousand AUD | 0.0% |
| 2012 Q3 | 580.52 Thousand AUD | -17.44% |
| 2012 Q2 | 703.15 Thousand AUD | 0.0% |
| 2012 Q1 | 703.15 Thousand AUD | 0.0% |
| 2011 Q4 | 703.15 Thousand AUD | 0.0% |
| 2011 FY | 4.67 Million AUD | 144.92% |
| 2011 Q3 | 703.15 Thousand AUD | -43.15% |
| 2011 Q1 | 1.23 Million AUD | 0.0% |
| 2011 Q2 | 1.23 Million AUD | 0.0% |
| 2010 Q3 | 1.23 Million AUD | 485.95% |
| 2010 Q4 | 1.23 Million AUD | 0.0% |
| 2010 FY | 1.91 Million AUD | -52.36% |
| 2010 Q1 | 211.07 Thousand AUD | 0.0% |
| 2010 Q2 | 211.07 Thousand AUD | 0.0% |
| 2009 Q1 | -272.17 Thousand AUD | 0.0% |
| 2009 Q4 | 211.07 Thousand AUD | 0.0% |
| 2009 Q2 | -272.17 Thousand AUD | 0.0% |
| 2009 Q3 | 211.07 Thousand AUD | 177.55% |
| 2009 FY | 4 Million AUD | 199.27% |
| 2008 Q3 | -272.17 Thousand AUD | -206.14% |
| 2008 Q1 | 256.42 Thousand AUD | 0.0% |
| 2008 FY | 1.33 Million AUD | 20.13% |
| 2008 Q4 | -272.17 Thousand AUD | 0.0% |
| 2008 Q2 | 256.42 Thousand AUD | 0.0% |
| 2007 Q3 | 256.42 Thousand AUD | 0.0% |
| 2007 FY | 1.11 Million AUD | 0.0% |
| 2007 Q4 | 256.42 Thousand AUD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Bright Green Corporation | 8.25 Million USD | -264.152% |
| Alpha Teknova, Inc. | 45.85 Million USD | 34.467% |
| ANI Pharmaceuticals, Inc. | 195.98 Million USD | 84.666% |
| Aquestive Therapeutics, Inc. | 44.85 Million USD | 32.998% |
| Collegium Pharmaceutical, Inc. | 159.2 Million USD | 81.123% |
| Cosmos Health Inc. | 26.18 Million USD | -14.79% |
| Journey Medical Corporation | 54.59 Million USD | 44.952% |
| Embecta Corp. | 528.4 Million USD | 94.312% |
| Esperion Therapeutics, Inc. | 271.89 Million USD | 88.947% |
| Dynavax Technologies Corporation | 219.14 Million USD | 86.286% |
| Intra-Cellular Therapies, Inc. | 590 Million USD | 94.906% |
| Pacira BioSciences, Inc. | 326.37 Million USD | 90.792% |
| PainReform Ltd. | 9.58 Million USD | -213.575% |
| Sunshine Biopharma, Inc. | 13.12 Million USD | -128.984% |
| Sunshine Biopharma, Inc. | 13.12 Million USD | -128.984% |
| SCYNEXIS, Inc. | 51.84 Million USD | 42.036% |
| Safety Shot Inc | 12.1 Million USD | -148.173% |
| China SXT Pharmaceuticals, Inc. | 3.06 Million USD | -879.184% |
| Procaps Group, S.A. | 199.47 Million USD | 84.934% |
| Theratechnologies Inc. | 72.75 Million USD | 58.693% |
| Harrow Health, Inc. | 89.97 Million USD | 66.598% |
| Sonoma Pharmaceuticals, Inc. | 9.44 Million USD | -218.156% |
| Biofrontera Inc. | 39.95 Million USD | 24.79% |
| DURECT Corporation | 43.71 Million USD | 31.252% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | 94.319% |
| Cronos Group Inc. | 96.7 Million USD | 68.924% |
| OptiNose, Inc. | 85.1 Million USD | 64.686% |
| Ironwood Pharmaceuticals, Inc. | 232.12 Million USD | 87.053% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | 23.242% |
| RedHill Biopharma Ltd. | -9.56 Million USD | 414.329% |
| Organogenesis Holdings Inc. | 314.13 Million USD | 90.433% |
| Guardion Health Sciences, Inc. | 9.73 Million USD | -208.843% |
| Cumberland Pharmaceuticals Inc. | 43.04 Million USD | 30.175% |
| Radius Health, Inc. | 265.92 Million USD | 88.699% |
| Universe Pharmaceuticals INC | 13.84 Million USD | -117.116% |
| ProPhase Labs, Inc. | 37.85 Million USD | 20.604% |
| Phibro Animal Health Corporation | 260.29 Million USD | 88.454% |
| Procaps Group S.A. | 187.24 Million USD | 83.95% |
| Alvotech | 285.43 Million USD | 89.471% |
| TherapeuticsMD, Inc. | 9.82 Million USD | -205.883% |
| Viatris Inc. | 5.96 Billion USD | 99.496% |
| Rockwell Medical, Inc. | 15.37 Million USD | -95.479% |
| Aytu BioPharma, Inc. | 59.84 Million USD | 49.778% |
| SIGA Technologies, Inc. | 22.04 Million USD | -36.338% |
| Tilray Brands, Inc. | 251.35 Million USD | 88.044% |
| Lifecore Biomedical, Inc. | 49.03 Million USD | 38.715% |
| Shineco, Inc. | 17.94 Million USD | -67.444% |
| PetIQ, Inc. | 192.72 Million USD | 84.406% |
| Regencell Bioscience Holdings Limited | 3.99 Million USD | -652.993% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | 98.118% |
| Alimera Sciences, Inc. | 62.64 Million USD | 52.023% |
| Silver Spike Investment Corp. | 762.49 Thousand USD | -3841.418% |
| Assertio Holdings, Inc. | 368.58 Million USD | 91.846% |
| Shuttle Pharmaceuticals Holdings, Inc. | 5.88 Million USD | -410.622% |
| Petros Pharmaceuticals, Inc. | 17.8 Million USD | -68.756% |
| Clever Leaves Holdings Inc. | 21.16 Million USD | -41.967% |
| Cyclo Therapeutics, Inc. | 21.04 Million USD | -42.823% |
| Avadel Pharmaceuticals plc | 164.96 Million USD | 81.782% |
| Hempacco Co., Inc. | 7.59 Million USD | -295.619% |
| Talphera, Inc. | 11.99 Million USD | -150.567% |
| Alvotech | 285.43 Million USD | 89.471% |
| Eagle Pharmaceuticals, Inc. | 140.71 Million USD | 78.642% |
| Lantheus Holdings, Inc. | 344.9 Million USD | 91.286% |
| Currenc Group, Inc. | 24 Million USD | -25.21% |
| Kamada Ltd. | 45.42 Million USD | 33.842% |
| Indivior PLC | 911 Million USD | 96.701% |
| Evoke Pharma, Inc. | 12.4 Million USD | -142.175% |
| Flora Growth Corp. | 10.57 Million USD | -184.082% |
| Cyclo Therapeutics, Inc. | 21.04 Million USD | -42.823% |
| Evolus, Inc. | 189.75 Million USD | 84.163% |
| HUTCHMED (China) Limited | 436.23 Million USD | 93.111% |
| Amphastar Pharmaceuticals, Inc. | 154.13 Million USD | 80.502% |
| Akanda Corp. | 3.48 Million USD | -762.722% |